| アブストラクト | INTRODUCTION: Long-term medication leads some people with HIV (PWH) to limited treatment options (LTO) due to multiple factors. The present study investigated the prevalence of PWH with LTO in Japan and their clinical characteristics, persistence, and adherence. METHODS: PWH who received antiretroviral therapy (ART) between 2017 and 2022 were identified in the Medical Data Vision (MDV) Japanese claims database. PWH with LTO were defined as: 1) receiving regimens indicative for LTO or 2) having a complex treatment history (>/=4 different core agents, >/=11 ART agents). Prevalence by calendar year, clinical characteristics, persistence, and adherence measured by the proportion of days covered (PDC) of ART were investigated. RESULTS: A total of 5740 PWH were included, and 207 (3.6 %) were identified as LTO. Mean (SD) age was 50.3 (11.8) years, 148 (71.5 %) had evidence of AIDS-defining condition, and 25 (12.1 %) had hemophilia. The prevalence of PWH with LTO increased from 2.58 % in 2017 to 3.55 % in 2022. Persistence at 1 year was estimated as 70.3 % and mean PDC through 1 year was 96.7 %. CONCLUSION: Between the years 2017-2022, 3.6 % (approximately 200) Japanese PWH were identified as having LTO. The results of this analysis found clinical characteristics of PWH with LTO as older age and higher percentages with an AIDS-defining condition and hemophilia than the general HIV population. Low persistence indicates that treatment optimization is required in this population. These results will help health care providers to understand the clinical characteristics of PWH with LTO and may contribute to the establishment of appropriate treatment strategies. |
|---|
| ジャーナル名 | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
|---|
| 投稿日 | 2024/6/14 |
|---|
| 投稿者 | Harada, Keisuke; Piao, Yi; Rubino, Annalisa; Lee, KuanYeh; Mezzio, Dylan; Taguchi, Nao; Tanikawa, Tetsuya; Gatanaga, Hiroyuki |
|---|
| 組織名 | Gilead Sciences K.K., Tokyo, Japan. Electronic address:;keisuke.harada@gilead.com.;Gilead Sciences K.K., Tokyo, Japan.;Gilead Sciences Europe Ltd., Uxbridge, UK.;Gilead Sciences, Taipei, Taiwan.;Gilead Sciences, Foster City, USA.;AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo,;Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38871253/ |
|---|
